CN108264489B - 一种在水中合成喹唑啉的方法 - Google Patents
一种在水中合成喹唑啉的方法 Download PDFInfo
- Publication number
- CN108264489B CN108264489B CN201611269654.XA CN201611269654A CN108264489B CN 108264489 B CN108264489 B CN 108264489B CN 201611269654 A CN201611269654 A CN 201611269654A CN 108264489 B CN108264489 B CN 108264489B
- Authority
- CN
- China
- Prior art keywords
- water
- reaction
- cat
- cdcl
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 15
- 230000002194 synthesizing effect Effects 0.000 title abstract description 5
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- GVOYKJPMUUJXBS-UHFFFAOYSA-N 2-(aminomethyl)aniline Chemical compound NCC1=CC=CC=C1N GVOYKJPMUUJXBS-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000006243 chemical reaction Methods 0.000 claims abstract description 15
- 239000003054 catalyst Substances 0.000 claims abstract description 10
- 150000004696 coordination complex Chemical class 0.000 claims abstract description 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims abstract 2
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 claims abstract 2
- -1 methoxyphenyl Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 230000035484 reaction time Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 abstract description 42
- 239000011541 reaction mixture Substances 0.000 abstract description 21
- 238000002390 rotary evaporation Methods 0.000 abstract description 21
- 239000012327 Ruthenium complex Substances 0.000 abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 5
- 239000001257 hydrogen Substances 0.000 abstract description 5
- 229910052741 iridium Inorganic materials 0.000 abstract description 5
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 abstract description 5
- 239000007800 oxidant agent Substances 0.000 abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 3
- 125000004429 atom Chemical group 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract description 2
- 230000001590 oxidative effect Effects 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 78
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 19
- 239000003208 petroleum Substances 0.000 description 19
- 238000004983 proton decoupled 13C NMR spectroscopy Methods 0.000 description 19
- 239000007805 chemical reaction reactant Substances 0.000 description 8
- 150000003246 quinazolines Chemical class 0.000 description 5
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 4
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 4
- VYFOAVADNIHPTR-UHFFFAOYSA-N isatoic anhydride Chemical compound NC1=CC=CC=C1CO VYFOAVADNIHPTR-UHFFFAOYSA-N 0.000 description 4
- ISXXPTVVLCNRRS-UHFFFAOYSA-N 2-(4-tert-butylphenyl)quinazoline Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=NC=C(C=CC=C2)C2=N1 ISXXPTVVLCNRRS-UHFFFAOYSA-N 0.000 description 3
- BIMXRUQUCRQDJV-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)quinazoline Chemical compound C1=C(Cl)C(Cl)=CC=C1C1=NC=C(C=CC=C2)C2=N1 BIMXRUQUCRQDJV-UHFFFAOYSA-N 0.000 description 2
- VNAVDRAEEFUSOQ-UHFFFAOYSA-N 2-(4-bromophenyl)quinazoline Chemical compound C1=CC(Br)=CC=C1C1=NC=C(C=CC=C2)C2=N1 VNAVDRAEEFUSOQ-UHFFFAOYSA-N 0.000 description 2
- NMJRUVIOYRDYQN-UHFFFAOYSA-N 2-(4-chlorophenyl)quinazoline Chemical compound C1=CC(Cl)=CC=C1C1=NC=C(C=CC=C2)C2=N1 NMJRUVIOYRDYQN-UHFFFAOYSA-N 0.000 description 2
- BYHOMJKKAFHBRI-UHFFFAOYSA-N 2-(4-methylphenyl)quinazoline Chemical compound C1=CC(C)=CC=C1C1=NC=C(C=CC=C2)C2=N1 BYHOMJKKAFHBRI-UHFFFAOYSA-N 0.000 description 2
- FFDCRTCRDMDDHZ-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)quinazoline Chemical compound CS(=O)(=O)C1=CC=C(C=C1)C1=NC2=CC=CC=C2C=N1 FFDCRTCRDMDDHZ-UHFFFAOYSA-N 0.000 description 2
- VQVKOBQYJDSKGU-UHFFFAOYSA-N 2-(4-propan-2-ylphenyl)quinazoline Chemical compound C(C)(C)C1=CC=C(C=C1)C1=NC2=CC=CC=C2C=N1 VQVKOBQYJDSKGU-UHFFFAOYSA-N 0.000 description 2
- GWBVDHNRTRASFL-UHFFFAOYSA-N 2-(furan-2-yl)quinazoline Chemical compound C1=COC(C=2N=C3C=CC=CC3=CN=2)=C1 GWBVDHNRTRASFL-UHFFFAOYSA-N 0.000 description 2
- OEYSIVBTZRFCAK-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]quinazoline Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NC=C(C=CC=C2)C2=N1 OEYSIVBTZRFCAK-UHFFFAOYSA-N 0.000 description 2
- JQVSFNUSJHDNGH-UHFFFAOYSA-N 2-cyclohexylquinazoline Chemical compound C1CCCCC1C1=NC=C(C=CC=C2)C2=N1 JQVSFNUSJHDNGH-UHFFFAOYSA-N 0.000 description 2
- ZTTOAIVNQMQGID-UHFFFAOYSA-N 2-naphthalen-2-ylquinazoline Chemical compound C1=CC=CC2=NC(C3=CC4=CC=CC=C4C=C3)=NC=C21 ZTTOAIVNQMQGID-UHFFFAOYSA-N 0.000 description 2
- AWAOSBFCHKVBDB-UHFFFAOYSA-N 2-pentylquinazoline Chemical compound C1=CC=CC2=NC(CCCCC)=NC=C21 AWAOSBFCHKVBDB-UHFFFAOYSA-N 0.000 description 2
- VDDAVZWCRBHDLQ-UHFFFAOYSA-N 2-phenylquinazoline Chemical class C1=CC=CC=C1C1=NC=C(C=CC=C2)C2=N1 VDDAVZWCRBHDLQ-UHFFFAOYSA-N 0.000 description 2
- PGOHIRZWBFOSRW-UHFFFAOYSA-N 2-thiophen-2-ylquinazoline Chemical class C1=CSC(C=2N=C3C=CC=CC3=CN=2)=C1 PGOHIRZWBFOSRW-UHFFFAOYSA-N 0.000 description 2
- XQNVDQZWOBPLQZ-UHFFFAOYSA-N 4-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=C(C=O)C=C1 XQNVDQZWOBPLQZ-UHFFFAOYSA-N 0.000 description 2
- OTXINXDGSUFPNU-UHFFFAOYSA-N 4-tert-butylbenzaldehyde Chemical compound CC(C)(C)C1=CC=C(C=O)C=C1 OTXINXDGSUFPNU-UHFFFAOYSA-N 0.000 description 2
- HTWJLGYTGTXIPA-UHFFFAOYSA-N 7-chloro-2-(4-chlorophenyl)quinazoline Chemical compound ClC1=CC=C2C=NC(=NC2=C1)C1=CC=C(C=C1)Cl HTWJLGYTGTXIPA-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- WTWBUQJHJGUZCY-UHFFFAOYSA-N cuminaldehyde Chemical compound CC(C)C1=CC=C(C=O)C=C1 WTWBUQJHJGUZCY-UHFFFAOYSA-N 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- ZSTNQGNEBJJIQO-UHFFFAOYSA-N 2-(4-chlorophenyl)-5-fluoroquinazoline Chemical compound N=1C=C2C(F)=CC=CC2=NC=1C1=CC=C(Cl)C=C1 ZSTNQGNEBJJIQO-UHFFFAOYSA-N 0.000 description 1
- WVGOZBCLJFXGTE-UHFFFAOYSA-N 2-(4-methoxyphenyl)quinazoline Chemical compound C1=CC(OC)=CC=C1C1=NC=C(C=CC=C2)C2=N1 WVGOZBCLJFXGTE-UHFFFAOYSA-N 0.000 description 1
- YXHQROMOUZVGCF-UHFFFAOYSA-N 2-(aminomethyl)-4-fluoroaniline Chemical compound NCC1=CC(F)=CC=C1N YXHQROMOUZVGCF-UHFFFAOYSA-N 0.000 description 1
- SRJQMTVOAGWOGP-UHFFFAOYSA-N 2-(aminomethyl)-5-chloroaniline Chemical compound NCC1=CC=C(Cl)C=C1N SRJQMTVOAGWOGP-UHFFFAOYSA-N 0.000 description 1
- RTIPTIXPHDGIHD-UHFFFAOYSA-N 2-(aminomethyl)-5-methylaniline Chemical compound CC1=CC=C(CN)C(N)=C1 RTIPTIXPHDGIHD-UHFFFAOYSA-N 0.000 description 1
- MAONDQUFXOWBPT-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]quinazoline Chemical compound FC(OC1=CC=C(C=C1)C1=NC2=CC=CC=C2C=N1)(F)F MAONDQUFXOWBPT-UHFFFAOYSA-N 0.000 description 1
- ZWUSBSHBFFPRNE-UHFFFAOYSA-N 3,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1Cl ZWUSBSHBFFPRNE-UHFFFAOYSA-N 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- HRDLKQWYHGPZOM-UHFFFAOYSA-N 4-chloro-2-(4-chlorophenyl)quinazoline Chemical compound C1=CC(Cl)=CC=C1C1=NC(Cl)=C(C=CC=C2)C2=N1 HRDLKQWYHGPZOM-UHFFFAOYSA-N 0.000 description 1
- PSVPUHBSBYJSMQ-UHFFFAOYSA-N 4-methylsulfonylbenzaldehyde Chemical compound CS(=O)(=O)C1=CC=C(C=O)C=C1 PSVPUHBSBYJSMQ-UHFFFAOYSA-N 0.000 description 1
- 241001249193 Artemisia campestris Species 0.000 description 1
- 241000194370 Cyclocephala pan Species 0.000 description 1
- 244000166652 Cymbopogon martinii Species 0.000 description 1
- 241001654709 Neoaleurodiscus fujii Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000000665 anti-chemotactic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种合成喹唑啉衍生物的方法,其步骤为:在反应容器中,加入醛、邻氨基苄胺、水溶性金属络合物催化剂(铱或钌络合物催化剂)、溶剂水,反应混合物在容器中反应数小时后,冷却到室温,旋转蒸发除去溶剂,然后通过柱分离,得到目标化合物。和已经报道过的文献相比,本发明使用水溶性的铱或钌络合物,反应只需要在水中加热进行,反应释放环境友好的氢气,无需要氧化剂或者氢的受体参与,展现了高的原子经济性和环境友好;因此,该反应符合绿色化学的要求,具有广阔的发展前景。
Description
技术领域
本发明属有机合成化学技术领域,具体涉及在水中一种喹唑啉的合成方法。
背景技术
喹唑啉代表着一类重要的结构单元,广泛存在于天然产物和合成药物中(a)J.P.Michael,Nat.Prod.Rep.2004,21,650-668;b)J.P.Michael,Nat.Prod.Rep.2005,22,627-646;c)J.P.Michael,Nat.Prod.Rep.2007,24,223-246;d)J.P.Michael,Nat.Prod.Rep.2008,25,166-187,I.Khan,A.Ibrar,W.Ahmed,A.Saeed,Eur.J.Med.Chem.2015,90,124-169)。
喹唑啉也展现出广泛的生物活性。最近的例子包括热力学二肽酶-4抑制剂,人体恶性胶质瘤抗增殖剂,干细胞因子受体抗趋化剂等等。(a)G.Schnapp,T.Klein,Y.Hoevels,R.A.Bakker,H.Nar,J.Med.Chem.2016,59,7466-7477;b)J.B.Smaill,A.J.Gonzales,J.A.Spicer,H.Lee,J.E.Reed,K.Sexton,I.W.Althaus,T.Zhu,S.L.Black,A.Blaser,W.A.Denny,P.A.Ellis,S.Fakhoury,P.J.Harvey,K.Hook,F.O.J.McCarthy,B.D.Palmer,F.Rivault,K.Schlosser,T.Ellis,A.M.Thompson,E.Trachet,R.T.Winters,H.Tecle,A.Bridges,J.Med.Chem.2016,59,8103-8124;c)S.Castellano,S.Taliani,M.Viviano,C.Milite,E.D.Pozzo,B.Costa,E.Barresi,A.Bruno,S.Cosconati,L.Marinelli,G.Greco,E.Novellino,G.Sbardella,F.D.Settimo,C.Martini,J.Med.Chem.2014,57,2413-2428;c)C.Wu,J.Song,K.Chang,J.Jan,C.Chen,M.Chou,K.Yeh,Y.Wong,C.Tseng,S.Wu,C.Yeh,C.Huang,M.Wang,A.A.Sadani,C.Chang,C.Cheng,L.K.Tsou,K.Shia,J.Med.Chem.2015,58,2315-2325)。
由于喹唑啉的重要性,大量的合成方法已经发展。最通用和有效的方法是2-氨基苄胺与醛发生反应生成半缩醛,然后在氧化剂的参与下,生成目标产物。然而,这些程序要求使用大量有毒的氧化剂,例如DDQ,四氯苯醌,二氧化锰,次氯酸钠或不饱和烯烃作为缚氢剂。而且,这些程序通常要在有机溶液中进行,导致产生大量的废液。(For selectedexamples,see:a)C.C.Malakar,A.Baskakova,J.Conrad,U.Beifuss,Chem.-Eur.J.2012,18,8882;b)B.Han,X.L.Yang,C.Wang,Y.W.Bai,T.C.Pan,X.Chen,W.Yu,J.Org.Chem.2012,77,1136;c)Y.Ohta,Y.Tokimizu,S.Oishi,N.Fujii,H.Ohno,Org.Lett.2010,12,3963-3965;d)Y.Z.Yan,Y.H.Zhang,C.T.Feng,Z.G.Zha,Z.Y.Wang,Angew.Chem.Int.Ed.2012,51,8077;e)J.Lin,F.Zhang,Y.Long,Org.Lett.2014,16,2822-2825;f)M.M.Chen,M.Zhang,B.Xiong,Z.D.Tan,W.Lv,H.F.Jiang,Org.Lett.2014,16,6028;g)L.Xu,H.Li,Z.Liao,K.Lou,H.Xie,H.Li,W.Wang,Org.Lett.2015,17,3434-3437;h)Z.Shen,P.Yang,Y.Tang,J.Org.Chem.2016,81,309-317;i)C.Xu,F.Jia,Z.Zhou,S.Zheng,H.Li,A.Wu,J.Org.Chem.2016,81,3000-3006;j)Z.Lv,B.Wang,Z.Hu,Y.Zhou,W.Yu,J.Chang,J.Org.Chem.2016,81,9924-9930;k)X.Cheng,H.Wang,F.Xiao,G.Deng,Green Chem.2016,18,5773-5776;l)J.Wang,S.Zha,K.Chen,F.Zhang,C.Song,J.Zhu,Org.Lett.2016,18,2062-2065;m)X.Wang,A.Lerchen,F.Glorius,Org.Lett.2016,18,2090-2093;n)X.Wang,N.Jiao,Org.Lett.2016,18,2150-2153)
发明内容
本发明的目的在于提供一种合成喹唑啉衍生物的方法。
本发明通过下述技术方案实现:一种合成喹唑啉衍生物(式Ⅰ)的方法,
其包含化合物醛(式II)
与化合物邻氨基苄醇(式III)反应
反应是在水溶性金属络合物催化剂和无碱的条件下发生,其反应通式为
其中,R1选自甲基,卤代基;
R2代表一个取代基,选自C1-C7烷基、芳基、甲基苯基、甲氧基苯基、三氟甲基苯基、三氟甲氧基苯基、卤代苯基、萘基、呋喃基或噻吩基。
本发明的具体方案通过下述步骤实现:
在反应容器中,加入醛、邻氨基苄胺、水溶性金属络合物催化剂(铱或钌络合物催化剂)、溶剂水,反应混合物在容器中反应数小时后,冷却到室温,旋转蒸发除去溶剂,然后通过柱分离,得到目标化合物。
其中,铱或钌络合物催化剂优选[Cp*Ir(bpy)Cl]Cl(bpy=2,2’-bipyridine)(cat.1)、[Cp*Ir(NH3)3][Cl]2(cat.2)、[Cp*Ir(H2O)3][OTf]2(cat.3)、[Cp*Ir(bpy)(H2O)][OTf]2(cat.4)、[Cp*Ir(6,6’-(OMe)2bpy)(H2O)][OTf]2(cat.5)、[Cp*Ir(6,6’-(OH)2bpy)(H2O)][OTf](cat.6)或[(p-cymene)Ru(6,6’-(OH)2bpy)(H2O)][OTf](cat.7)中任意一种,其结构分别如下:
进一步的,催化剂的用量相对于醛的摩尔比为1-2mol%;化合物邻氨基苄醇相对于醛摩尔比为1:1。
和已经报道过的文献相比,本发明使用水溶性的铱或钌络合物,反应只需要在水中加热进行,反应释放环境友好的氢气,无需要氧化剂或者氢的受体参与,展现了高的原子经济性和环境友好;因此,该反应符合绿色化学的要求,具有广阔的发展前景。
具体实施方式
展示一下实例来说明本发明的某些实施例,且不应解释为限制本发明的范围。对本发明公开的内容可以同时从材料,方法和反应条件上进行许多改进,变化和改变。所有这些改进,变化和改变均确定地落入本发明的精神和范围之内。
实施例1:2-(4-氯苯基)喹唑啉
2-(4-chlorophenyl)quinazoline
将对氯苯甲醛(70mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:76%。
1H NMR(500MHZ,CDCl3)δ9.46(s,1H),8.57(d,J=8.6Hz,2H),8.07(d,J=8.6Hz,1H),7.90(m,2H),7.62(t,J=7.5Hz,1H),7.50(d,J=8.7Hz,2H);13C{1H}NMR(125MHZ,CDCl3)δ160.5,160.1,150.7,136.8,136.5,134.2,129.9,128.8,128.6,127.4,127.1,123.6。
实施例2:2-(3,4-二氯苯基)喹唑啉
2-(3,4-dichlorophenyl)quinazoline
将3,4-二氯苯甲醛(86mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:83%。
1H NMR(500MHZ,CDCl3)δ9.45(s,1H),8.75(d,J=2.0Hz,1H),8.46(dd,J=8.5Hzand 2.0Hz,1H),8.07(d,J=8.3Hz,1H),7.92(t,J=7.8Hz,2H),7.64(t,J=7.5Hz,1H),7.58(d,J=8.4Hz,1H);13C{1H}NMR(125MHZ,CDCl3)δ160.5,158.8,150.6,138.0,134.7,134.4,132.9,130.5,130.4,128.6,127.7,127.6,127.1,123.7。
实施例3:2-(4-溴苯基)喹唑啉
2-(4-bromophenyl)quinazoline
将对溴苯甲醛(92mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:81%
1H NMR(500MHZ,CDCl3)δ9.45(s,1H),8.49(d,J=8.3Hz,2H),8.06(d,J=8.3Hz,1H),7.90(m,2H),7.61(m,3H);13C{1H}NMR(125MHZ,CDCl3)δ160.5,160.1,150.7,137.0,134.2,131.7,130.1,128.6,127.4,127.1,125.4,123.6。
实施例4:2-(4-甲磺酰基苯基)喹唑啉
2-(4-(methylsulfonyl)phenyl)quinazoline
将对甲磺酰基苯甲醛(92mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:80%。
1H NMR(500MHZ,CDCl3)δ9.50(s,1H),8.83(d,J=8.0Hz,2H),8.09(t,J=10.3Hz,2H),7.95(t,J=9.2Hz,2H),7.68(t,J=7.3Hz,1H),3.12(s,3H);13C{1H}NMR(125MHZ,CDCl3)δ160.7,159.0,150.6,143.0,141.8,141.8,134.5,129.4,128.8,128.2,127.6,127.2,123.9,44.5。
实施例5:2-(4-三氟甲基苯基)喹唑啉
2-(4-(trifluoromethyl)phenyl)quinazoline
将对三氟甲基苯甲醛(87mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:72%。
1H NMR(500MHZ,CDCl3)δ9.49(s,1H),8.74(d,J=8.2Hz,2H),8.11(d,J=8.4Hz,1H),7.93(m,2H),7.78(d,J=8.2Hz,2H),7.65(t,J=7.5Hz,1H);13C{1H}NMR(125MHZ,CDCl3)δ160.5,159.5,150.6,141.3,134.3,132.2(q,JC-F=32.1Hz),128.8,128.7,127.8,127.1,125.5,125.4,125.3(q,JC-F=272.4Hz),123.8。
实施例6:2-(4-三氟甲氧基苯基)喹唑啉
2-(4-(trifluoromethoxy)phenyl)quinazoline
将对三氟甲氧基苯甲醛(95mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在空气中回流反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:70%。
1H NMR(500MHZ,CDCl3)δ9.46(s,1H),8.66(d,J=8.6Hz,2H),8.08(d,J=8.4Hz,1H),7.91(t,J=9.8Hz,2H),7.62(t,J=7.4Hz,1H),7.36(t,J=8.3Hz,2H);13C{1H}NMR(125MHZ,CDCl3)δ160.6,159.8,151.1,150.7,136.6,134.2,130.2,128.6,127.5,127.1,123.6,121.5(q,J=171.8Hz),120.7。
实施例7:2-(4-甲基苯基)喹唑啉
2-(4-methylphenyl)quinazoline
将对甲基苯甲醛(60mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:74%。
1H NMR(500MHZ,CDCl3)δ9.43(s,1H),8.50(d,J=7.9Hz,2H),8.06(d,J=8.4Hz,1H),7.87(m,2H),7.57(t,J=7.4Hz,1H),7.33(d,J=7.9Hz,2H),2.44(s,3H);13C{1H}NMR(125MHZ,CDCl3)δ161.1,160.4,150.8,140.8,135.3,134.0,129.4,128.5,127.1,127.0,123.5,21.5。
实施例8:2-(4-异丙基苯基)喹唑啉
2-(4-isopropylphenyl)quinazoline
将对异丙基苯甲醛(74mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:72%。
1H NMR(500MHZ,CDCl3)δ9.45(s,1H),8.52(d,J=8.0Hz,2H),8.06(d,J=8.4Hz,1H),7.87(m,2H),7.57(t,J=7.4Hz,1H),7.39(d,J=8.0Hz,2H),2.98(m,1H),1.31(d,J=5.5Hz,6H);13C{1H}NMR(125MHZ,CDCl3)δ161.2,160.4,151.7,150.8,135.7,134.0,128.62,128.58,127.1,127.0,126.7,123.4,34.1,23.9。
实施例9:2-(4-叔丁基苯基)喹唑啉
2-(4-(tert-butyl)phenyl)quinazoline
将对叔丁基苯甲醛(81mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃回流反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:75%。
1H NMR(500MHZ,CDCl3)δ9.44(s,1H),8.53(d,J=8.4Hz,2H),8.06(d,J=8.3Hz,1H),7.86(m,2H),7.55(t,J=9.5Hz,3H),1.39(s,9H);13C{1H}NMR(125MHZ,CDCl3)δ161.1,160.4,153.9,150.8,135.3,133.9,128.6,128.3,127.1,127.0,125.6,123.5,34.8,31.2。
实施例10:2-(4-叔丁基苯基)喹唑啉
2-(4-methoxyphenyl)quinazoline
将对甲氧基苯甲醛(68mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在空气中回流反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:74%。
1H NMR(500MHZ,CDCl3)δ9.39(s,1H),8.56(d,J=8.6Hz,2H),8.01(d,J=8.6Hz,1H),7.84(t,J=7.4Hz,2H),7.52(t,J=7.4Hz,3H),3.88(s,3H);13C{1H}NMR(125MHZ,CDCl3)δ161.8,160.7,160.3,150.7,133.9,130.6,130.1,128.3,127.0,126.7,123.2,113.9,55.3。
实施例11:2-苯基喹唑啉
2-phenylquinazoline
将苯甲醛(53mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:70%。
1H NMR(500MHZ,CDCl3)δ9.47(s,1H),8.62(dd,J=1.6 and 8.2Hz,2H),8.09(d,J=8.4Hz,1H),7.89-7.93(m,2H),7.61(t,J=7.5Hz,1H),7.50-7.56(m,3H);13C{1H}NMR(125MHZ,CDCl3)δ161.0,160.4,150.7,138.0,134.0,130.5,128.6,128.5,127.2,127.1,123.5。
实施例12:2-(2-萘基)喹唑啉
2-(naphthalen-2-yl)quinazoline
将对三氟甲氧基苯甲醛(78mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:75%。
1H NMR(500MHZ,CDCl3)δ9.52(s,1H),9.16(s,1H),8.73(dd,J=8.6Hz and 1.5Hz,1H),8.14(d,J=8.4Hz,1H),8.04(m,1H),7.99(d,J=8.6Hz,1H),7.89(m,3H),7.62(t,J=7.5Hz,1H),7.52(m,2H);13C{1H}NMR(125MHZ,CDCl3)δ161.0,160.5,150.8,135.4,134.7,134.1,133.4,129.3,128.9,128.7,128.3,127.7,127.3,127.2,127.1,126.2,125.4,123.6。
实施例13:2-(2-呋喃基)喹唑啉
2-(furan-2-yl)quinazoline
将糠醛(48mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:64%。
1H NMR(500MHZ,CDCl3)δ9.39(s,1H),8.01(d,J=8.8Hz,1H),7.89(t,J=7.1Hz,2H),7.70(s,1H),7.59(t,J=7.4Hz,1H),7.46(d,J=3.2Hz,1H),7.62(m,1H);13C{1H}NMR(125MHZ,CDCl3)δ160.7,154.1,152.5,150.4,145.3,134.5,128.4,127.3,123.4,114.1,112.3。
实施例14:2-噻吩基喹唑啉
2-(thiophen-2-yl)quinazoline
将糠醛(56mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率71%。
1H NMR(500MHZ,CDCl3)δ9.34(s,1H),8.15(d,J=2.5Hz,1H),7.99(d,J=8.6Hz,1H),7.85(d,J=6.7Hz,2H),7.54(t,J=7.4Hz,1H),7.51(d,J=4.5Hz,1H),7.18(t,J=3.7Hz,1H);13C{1H}NMR(125MHZ,CDCl3)δ160.5,157.8,150.6,143.8,134.3,129.9,129.2,128.3,128.1,127.2,126.9,123.3。
实施例15:2-戊基喹唑啉
2-pentylquinazoline
将己醛(50mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率70%。
1H NMR(500MHZ,CDCl3)δ1H NMR(500MHz,CDCl3)δ9.35(s,1H),7.98(d,J=8.4Hz,1H),7.88(t,J=7.8Hz,2H),7.58(t,J=7.4Hz,1H),3.12(t,J=7.8Hz,1H),1.92(q,J=7.6Hz,2H),1.40(m,5H),0.91(t,J=7.0Hz,3H);13C{1H}NMR(125MHz,CDCl3)δ167.9,160.3,150.3,133.9,127.8,127.0,126.8,123.0,39.9,31.7,28.7,22.5,14.0.。
实施例16:2-环己基喹唑啉
2-cyclohexylquinazoline
将环己基(56mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、邻氨基苄胺(62.4mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在空气中回流反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率65%。
1H NMR(500MHZ,CDCl3)δ9.35(s,1H),7.99(d,J=8.5Hz,1H),7.87(t,J=7.8Hz,2H),7.58(d,J=7.5Hz,1H),3.05(tt,J1=11.8Hz,J2=3.4Hz,1H),2.08(d,J=13.1Hz,2H),1.90(d,J=13.1Hz,2H),1.78(m,3H),1.48(m,2H),1.38(m,1H);13C{1H}NMR(125MHZ,CDCl3)δ170.9,160.4,150.4,133.8,128.0,127.0,126.8,123.2,47.9,31.9,26.3,26.0.。
实施例17:2-(4-氯)-5-氟喹唑啉
2-(4-chlorophenyl)-5-fluoroquinazoline
将对氯苯甲醛(70mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、2-氨基-5-氟苄胺(70mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:78%。
1H NMR(500MHZ,CDCl3)δ9.72(s,1H),8.57(d,J=8.6Hz,2H),7.85(m,2H),7.50(d,J=8.6Hz,2H),7.25(m,1H);13C{1H}NMR(125MHZ,CDCl3)δ160.7,159.2,157.2,154.9(d,JC-F=3.7Hz),151.4,137.3,136.1,134.2(d,JC-F=9.0Hz),130.0,128.8,124.5(d,JC-F=4.1Hz),114.5(d,JC-F=15.8Hz),111.2(d,JC-F=18.6Hz).。
实施例18:7-氯-2-(4-氯苯基)喹唑啉
7-chloro-2-(4-chlorophenyl)quinazoline
将对氯苯甲醛(70mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、2-氨基-4-氯苄胺(78mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:70%
1H NMR(500MHZ,CDCl3)δ9.72(s,1H),8.58(d,J=8.6Hz,2H),7.86(m,2H),7.50(d,J=8.6Hz,2H),7.24(d,J=8.0Hz,1H);13C{1H}NMR(125MHZ,CDCl3)δ160.8,160.1,151.2,140.5,137.2,136.0,129.9,128.8,128.6,128.3,127.7,121.9.。
实施例19:7-氯-2-(4-甲基苯基)喹唑啉
7-chloro-2-(4-chlorophenyl)quinazoline
将对氯苯甲醛(70mg,0.5mmol)、cat.7(8.3mg,0.01mmol,2mol%)、2-氨基-4-甲基苄胺(68mg,0.5mmol)和水(1ml)依次加入到25mL克氏管中。反应混合物在130℃反应12小时后,冷却到室温。旋转蒸发除掉溶剂,然后通过柱层析(展开剂:石油醚/乙酸乙酯)得到纯净的目标化合物,产率:50%。
1H NMR(500MHZ,CDCl3)δ9.39(s,1H),8.54(d,J=8.5Hz,2H),7.84(t,J=8.4Hz,2H),7.48(q,3H),2.61(s,3H);13C{1H}NMR(125MHZ,CDCl3)δ159.9,159.8,150.9,145.6,136.8,136.5,129.8,129.4,128.8,127.5,126.8,121.8,22.3。
实施例20:
除用cat.1(6.2mg,0.01mmol,2mol%)代替cat.7,其它反应原料,条件和产物同实施例1,产率:28%。
实施例21:
除用cat.2(4.5mg,0.01mmol,2mol%)代替cat.7,其它反应原料,条件和产物同实施例1,收率:57%。
实施例22:
除用cat.3(8.1mg,0.01mmol,2mol%)代替cat.7,其它反应原料,条件和产物同实施例1,收率:53%。
实施例23:
除用cat.4(8.6mg,0.01mmol,2mol%)代替cat.7,其它反应原料,条件和产物同实施例1,收率:36%。
实施例24:
除用cat.5(9.2mg,0.01mmol,2mol%)代替cat.7,其它反应原料,条件和产物同实施例1,收率:50%。
实施例25:
除用cat.6(8.3mg,0.01mmol,2mol%)代替cat.7,其它反应原料,条件和产物同实施例1,收率:83%。
实施例26:
除用cat.8(8.0mg,0.01mmol,2mol%)代替cat.7,其它反应原料,条件和产物同实施例1,收率:43%。
实施例27:
除用cat.7(4.2mg,0.01mmol,1mol%),其它反应原料,条件和产物同实施例1,收率:62%。
实施例28:
除反应温度在120℃,其它反应原料,条件和产物同实施例1,收率:68%。
Claims (5)
2.如权利要求1所述的方法,其特征在于,水溶性金属络合物催化剂的用量相对于化合物醛的摩尔比为1-2mol%。
3.如权利要求1所述的方法,其特征在于,化合物邻氨基苄胺相对于化合物醛摩尔比为1:1。
4.如权利要求1所述的方法,其特征在于,所述反应在克氏 管进行。
5.如权利要求1所述的方法,其特征在于,反应时间为12小时以上。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611269654.XA CN108264489B (zh) | 2016-12-30 | 2016-12-30 | 一种在水中合成喹唑啉的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611269654.XA CN108264489B (zh) | 2016-12-30 | 2016-12-30 | 一种在水中合成喹唑啉的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108264489A CN108264489A (zh) | 2018-07-10 |
CN108264489B true CN108264489B (zh) | 2021-06-08 |
Family
ID=62771201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611269654.XA Expired - Fee Related CN108264489B (zh) | 2016-12-30 | 2016-12-30 | 一种在水中合成喹唑啉的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108264489B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110857301B (zh) * | 2018-08-23 | 2022-07-22 | 南京理工大学 | 一种制备tnni3k抑制剂的方法 |
-
2016
- 2016-12-30 CN CN201611269654.XA patent/CN108264489B/zh not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
A Cooperative Catalytic System of Platinum/Iridium Alloyed Nanoclusters and a Dimeric Catechol Derivative: An Efficient Synthesis of Quinazolines Through a Sequential Aerobic Oxidative Process;Hao Yuan,et al.;《Adv. Synth. Catal.》;20121231(第354期);第2899-2904页 * |
Acceptorless dehydrogenative condensation of o-aminobenzamides with aldehydes to quinazolinones in water catalyzed by a watersoluble iridium complex [Cp*Ir(H2O)3][OTf ]2;Feng Li,et al.;《Org. Chem. Front.》;20151231;第2015卷(第2期);第1589-1597页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108264489A (zh) | 2018-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5563449B2 (ja) | ピラゾールの調製方法 | |
Li et al. | Novel palladium-catalyzed cascade carboxylative annulation to construct functionalized γ-lactones in ionic liquids | |
EA024425B1 (ru) | Способ получения 2-(2,3-диметилфенил)-1-пропаналя с использованием хлорацетона | |
Bao et al. | An effective synthesis of bromoesters from aromatic aldehydes using tribromide ionic liquid based on L-prolinol as reagent and reaction medium under mild conditions | |
Gadilohar et al. | Choline peroxydisulfate oxidizing Bio-TSIL: triple role player in the one-pot synthesis of Betti bases and gem-bisamides from aryl alcohols under solvent-free conditions | |
CN108264489B (zh) | 一种在水中合成喹唑啉的方法 | |
Nasseri et al. | Cellulose sulfuric acid as a bio-supported and efficient solid acid catalyst for synthesis of pyrazoles in aqueous medium | |
KR20170017372A (ko) | 피라졸 카르복실산 유도체의 제조방법 | |
CN108409732B (zh) | 一种β-咔啉杂环化合物的绿色合成方法 | |
JP3536122B2 (ja) | 2−ヒドロキシアリールアルドキシムの製造方法 | |
CN112645887B (zh) | 一种喹唑啉酮衍生物的制备方法 | |
JP2004115519A (ja) | アルキンカルボン酸の製造方法 | |
CN110002961B (zh) | 一种去外消旋化合成手性醇的方法 | |
JP4303792B2 (ja) | キノロン誘導体の製造方法 | |
JPH04244041A (ja) | ハロゲノメチルケトン、特に1,1,1−トリフルオロアセトンの製造法 | |
CN102675125A (zh) | 一种4-氯-2-三氟乙酰基苯胺及其类似物的简便高效合成方法 | |
CN107400084B (zh) | 一种合成喹啉衍生物的方法 | |
Zang et al. | An efficient one‐pot synthesis of pyrazolone derivatives promoted by acidic ionic liquid | |
JP6764158B2 (ja) | カルボニル化合物の製造方法 | |
JP7403835B2 (ja) | 2-ヨードソ安息香酸類の製造方法 | |
CN109384645B (zh) | 一种合成仲醇的方法 | |
CN112159375B (zh) | 一种2,3-二氢呋喃类化合物的绿色制备方法 | |
JPS6284064A (ja) | 3−パ−フルオロアルキル−5−ヒドロキシイソオキサゾ−ル類 | |
CN107459530A (zh) | 一种新型硅基取代的1,3‑异喹啉二酮衍生物及其制备方法 | |
CN110283159B (zh) | 一锅法制备的2,4-二取代吡咯或2,3,4-三取代吡咯及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210608 |